-All Infants' and Children's TYLENOL® Products Containing Acetaminophen
Will Continue to Be Available in Canada-
MARKHAM, ON, May 5 /CNW/ - McNeil Consumer Healthcare division of
Johnson & Johnson Inc. (Canada) issued a statement today confirming
that all Infants' and Children's TYLENOL® products containing
acetaminophen will continue to be sold in Canada at their current concentrations.
The statement follows release of information yesterday that McNeil
Consumer Healthcare, division of McNeil-PPC, Inc. in the U.S., has made
a voluntary change to move to a single concentration of acetaminophen
for single ingredient Infants' and Children's TYLENOL® products sold in
the U.S. The change has been made to standardize dosing across their
products and age groups.
At this time there is no plan to move to a single concentration for
Infants' and Children's TYLENOL® products in Canada. In Canada, the
concentration of acetaminophen and dosing directions for pediatric
products is carefully regulated by Health Canada. The labelling
standard governing these products in Canada was updated in late 2009.
Acetaminophen has been used by millions of people throughout the world
for over three decades and has a well established record of
safety. Infants' and Children's TYLENOL® products continue to be safe
and effective when used as directed. Users should always carefully
read and follow label instructions.
Should parents have questions, they can call Johnson & Johnson Inc.'s
Consumer Contact Center number: 877-414-7711.
SOURCE McNeil Consumer Healthcare
For further information:
Krista Scaldwell, V.P. Communications and Public Affairs
Health Canada: 613-957-2983